Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Results of First General Meeting
Results of First General Meeting
Results of First General Meeting
eqs_en 
0 29.01.24
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
eqs_en 
0 24.01.24
Update on the Scheme and Publication of Notice of Second General Meeting
Update on the Scheme and Publication of Notice of Second General Meeting
Update on the Scheme and Publication of Notice of Second General Meeting
eqs_en 
0 23.01.24
Update on the Scheme and Resignation of Directors
Update on the Scheme and Resignation of Directors
Update on the Scheme and Resignation of Directors
eqs_en 
0 22.01.24
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
eqs_en 
0 19.01.24
Unaudited NAV for December 2023
Unaudited NAV for December 2023
Unaudited NAV for December 2023
eqs_en 
0 19.01.24
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
eqs_en 
0 08.01.24
Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
eqs_en 
0 05.01.24
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
eqs_en 
0 22.12.23
Unaudited NAV for November 2023
Unaudited NAV for November 2023
Unaudited NAV for November 2023
eqs_en 
0 13.12.23
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
eqs_en 
0 08.12.23
Edison issues flash on Foresight Solar Fund (FSFL): Q3 NAV and first sale of divestment programme
Edison issues flash on Foresight Solar Fund (FSFL): Q3 NAV and first sale of divestment programme
Edison issues flash on Foresight Solar Fund (FSFL): Q3 NAV and first sale of divestment programme
eqs_en 
0 17.11.23
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
eqs_en 
0 13.11.23
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
eqs_en 
0 10.11.23
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
eqs_en 
0 10.11.23
Unaudited NAV for October 2023
Unaudited NAV for October 2023
Unaudited NAV for October 2023
eqs_en 
0 08.11.23
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
eqs_en 
0 02.11.23
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
eqs_en 
0 01.11.23
Edison issues update on Foresight Solar Fund (FSFL): Generating solar power and cash
Edison issues update on Foresight Solar Fund (FSFL): Generating solar power and cash
Edison issues update on Foresight Solar Fund (FSFL): Generating solar power and cash
eqs_en 
0 30.10.23
Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet
Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet
Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet
eqs_en 
0 25.10.23
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
eqs_en 
0 24.10.23
Hardman & Co Research on City of London Investment Group (CLIG): Weak markets weigh on FUM
Hardman & Co Research on City of London Investment Group (CLIG): Weak markets weigh on FUM
Hardman & Co Research on City of London Investment Group (CLIG): Weak markets weigh on FUM
eqs_en 
0 17.10.23
Edison issues update on: Premier Miton Global Renewables Trust (PMGR) - Potential for real return
Edison issues update on: Premier Miton Global Renewables Trust (PMGR) - Potential for real return
Edison issues update on: Premier Miton Global Renewables Trust (PMGR) - Potential for real return
eqs_en 
0 13.10.23
Picton Property Income (PCTN) - Value-enhancing asset management
Picton Property Income (PCTN) - Value-enhancing asset management
Picton Property Income (PCTN) - Value-enhancing asset management
eqs_en 
0 13.10.23
Hardman & Co Analyst Interview on City of London Investment Group (CLIG): Performance pays dividends
Hardman & Co Analyst Interview on City of London Investment Group (CLIG): Performance pays dividends
Hardman & Co Analyst Interview on City of London Investment Group (CLIG): Performance pays dividends
eqs_en 
0 12.10.23